SurVaxM is engineered to be highly immunogenic, and is delivered through simple subcutaneous injection. Read More


Survivin is an endogenous cellular protein that prevents tumor cell death. It is not, however, generally present in normal adult cells. Survivin is the target of MimiVax SurVaxM.

  • SurVaxM has been proven to inhibit tumor growth and prolong survival of animals with brain, ovarian, renal, and prostate cancers. It also induces the lymphocytes of cancer patients to kill his/her own tumor cells in the laboratory.
  • Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer immunology, immunotherapy, 2010; 598:1211-1221
  • Fenstermaker RA,. Ciesielski MJ. Development of a Survivin Vaccine (SurVaxM) for Malignant Glioma. Expert Rev Vaccines 2014; 13:377–385.
  • Ciesielski MJ, Qiu, J, Fenstermaker RA. Survivin as a Cancer Vaccine Target. J Vaccines Vaccin 5:3, 2014.

MimiVax Immunotherapy: SurVaxM

See More

MimiVax, LLC

Elm & Carlton Streets

MRC 105

Buffalo, NY  14263


Pharmaceuticals for Oncology


MimiVax SurVaxM

MimiVax, LLC together with Roswell Park Cancer Institute will be presenting the results of their recently completed Phase I clinical study of SurVaxM in recurrent glioma patients at the 2015 American Association for Cancer Research Annual Meeting (AACR). 

"Phase I study of SurVaxM in patients with survivin-expressing recurrent malignant gliomas" - Abstract CT301
(Tuesday, Apr 21, 2015, 8:00AM-12:00PM; Poster Section 24, Board #1)